Glympse Bio Inc (Glympse Bio) is a biotechnology company that focuses on developing medical devices to diagnose and monitor inflammation and fibrotic, oncological indications and autoimmune diseases. It is investigating non-invasive biosensors to detect NASH (non-alcoholic steatohepatitis) by measuring changes in liver-associated protease activity. The company is also developing diagnostic devices to identify hepatocellular carcinoma (HCC),and tunable biosensors to diagnose autoimmune diseases, among others. Its biosensors are made-up of peptide molecules that are cleaved by disease-specific proteases. Glympse Bio is headquartered in Cambridge, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glympse Bio Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Glympse Bio Inc Company Overview
- Glympse Bio Inc Company Snapshot
- Glympse Bio Inc Pipeline Products and Ongoing Clinical Trials Overview
- Glympse Bio Inc - Pipeline Analysis Overview
- Glympse Bio Inc - Key Facts
- Glympse Bio Inc - Major Products and Services
- Glympse Bio Inc Pipeline Products by Development Stage
- Glympse Bio Inc Pipeline Products Overview
- Glympse Liver Test
- Glympse Liver Test Product Overview
- Nanoparticle-Based Sensor - Autoimmune Diseases
- Nanoparticle-Based Sensor - Autoimmune Diseases Product Overview
- Nanoparticle-Based Sensor - Fibrotic Diseases
- Nanoparticle-Based Sensor - Fibrotic Diseases Product Overview
- Nanoparticle-Based Sensor - Non Small Cell Lung Cancer
- Nanoparticle-Based Sensor - Non Small Cell Lung Cancer Product Overview
- Nanoparticle-Based Sensor - Pneumonia
- Nanoparticle-Based Sensor - Pneumonia Product Overview
- Nanoparticle-Based Sensor - Solid Tumors
- Nanoparticle-Based Sensor - Solid Tumors Product Overview
- Nanoparticle-Based Sensor - Tuberculosis
- Nanoparticle-Based Sensor - Tuberculosis Product Overview
- Ultrasensitive Diagnostic Test - HCC
- Ultrasensitive Diagnostic Test - HCC Product Overview
- Glympse Bio Inc - Key Competitors
- Glympse Bio Inc - Key Employees
- Glympse Bio Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Glympse Bio Inc, Recent Developments
- May 17, 2022: Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform
- Jul 20, 2021: Glympse Bio Appoints Matthew T. Navarro, J.D., as Chief Financial Officer
- Feb 02, 2021: Glympse Bio Names Jessica Atkinson Senior Vice President of Business Development
- Nov 08, 2019: Glympse Bio presents preclinical data supporting Its technology’s potential to improve NASH patient management
- Nov 04, 2019: Glympse Bio names Tracey Dawson as Chief Commercial Officer and Head of Strategy
- Aug 01, 2019: Pharmaceutical executive Francis Cuss joins Glympse Bio Board
- May 14, 2019: Glympse Bio names Wendy Winckler as chief scientific officer
- Dec 04, 2018: Glympse Bio names Caroline J Loew, Ph.D. President and Chief Executive Officer
- Nov 29, 2018: With these nanoparticles, a simple urine test could diagnose bacterial pneumonia
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Glympse Bio Inc Pipeline Products and Ongoing Clinical Trials Overview
- Glympse Bio Inc Pipeline Products by Equipment Type
- Glympse Bio Inc Pipeline Products by Indication
- Glympse Bio Inc, Key Facts
- Glympse Bio Inc, Major Products and Services
- Glympse Bio Inc Number of Pipeline Products by Development Stage
- Glympse Bio Inc Pipeline Products Summary by Development Stage
- Glympse Liver Test - Product Status
- Glympse Liver Test - Product Description
- Nanoparticle-Based Sensor - Autoimmune Diseases - Product Status
- Nanoparticle-Based Sensor - Autoimmune Diseases - Product Description
- Nanoparticle-Based Sensor - Fibrotic Diseases - Product Status
- Nanoparticle-Based Sensor - Fibrotic Diseases - Product Description
- Nanoparticle-Based Sensor - Non Small Cell Lung Cancer - Product Status
- Nanoparticle-Based Sensor - Non Small Cell Lung Cancer - Product Description
- Nanoparticle-Based Sensor - Pneumonia - Product Status
- Nanoparticle-Based Sensor - Pneumonia - Product Description
- Nanoparticle-Based Sensor - Solid Tumors - Product Status
- Nanoparticle-Based Sensor - Solid Tumors - Product Description
- Nanoparticle-Based Sensor - Tuberculosis - Product Status
- Nanoparticle-Based Sensor - Tuberculosis - Product Description
- Ultrasensitive Diagnostic Test - HCC - Product Status
- Ultrasensitive Diagnostic Test - HCC - Product Description
- Glympse Bio Inc, Key Employees
- Glossary
- Glympse Bio Inc Pipeline Products by Equipment Type
- Glympse Bio Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioHybrid Solutions LLC
- Innovogene Biosciences Inc
- LifeSignals
- Innovogene Biosciences Inc
- LifeSignals
- BioHybrid Solutions LLC
